Lupus erythematosus
☆ Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
Ew wekî erythema piçek mor xuya dike.
Reşîka bilbilê ku bi gelemperî li ser rû xuya dike.
References
Nasîn û dabeşkirina cutaneous lupus erythematosus (CLE) kêşeyên tespîtkirinê derdixe holê, wê ji systemic lupus erythematosus bi tevlêbûna çerm cuda dike. Lêkolînên dawîn li ser faktorên genetîkî, hawîrdor û immunolojîk ên bingehîn ên CLE ronî dikin. Induction narkotîkê bi taybetî ji bo CLE wekî yek ji girîngtirîn tehlûkê derketiye holê. Dermankirin tedawiyên herêmî û pergalî, tevî biyolojîkên sozdar (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , bi bandorkeriya xwe di ceribandinên klînîkî de vedihewîne.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) pirsgirêkên cûrbecûr yên çerm vedigire, ku hin ji wan dikarin bi pirsgirêkên tenduristiyê yên berfireh ve girêdayî bin. Ew di nav celebên cûda de, wekî acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) , tê categorîzekirin. CCLE discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus pêk tîne.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus komek nexweşiyên otoîmmune ye ku dikare bandorê li beşên cûda yên laş bike. Hin cûre, wekî systemic lupus erythematosus (SLE) , bandorê li gelek organan dikin, lê yên din, wekî cutaneous lupus erythematosus (CLE) , bi giranî bandorê li çerm dikin. Em celebên CLE-ê li ser bingeha tevliheviya nîşanên klînîkî, muayeneya tevnvîsê, û ceribandinên xwînê kategorîze dikin, lê di navbera kesan de gelek cûdahî hene. Pirsgirêkên çerm bi gelemperî ji ber faktorên wekî ronahiya rojê, cixare, an hin dermanan çêdibin.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Sedema lupus erythematosus ne diyar e. Di nav cêwîyên wek hev de, ger yek bandor bibe şansê 24% heye ku yê din jî bibe. Her weha tê bawer kirin ku hormonên zayendî yên jinan, tîrêjên rojê, cixarekêş, kêmbûna vîtamîn D, û hin enfeksiyonan jî xetereyê zêde dikin.
Dibe ku dermankirin NSAIDs, kortikosteroîd, immunosuppressants, hydroxychloroquine, û methotrexate bin. Her çend corticosteroids bi bandor in, karanîna dirêj-dirêj dibe sedema bandorên alî.